Before visiting, please review our current visitor policies and COVID-19 information.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Zymeworks ZWI-ZW25-201

Trial Overview

Official Title

Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), And Colorectal Cancer (CRC) 

Study Purpose

To determine if the experimental study drug ZW25 is safe and effective in the treatment of HER2-expressing GI cancers

Diagnosis

Patient who have been diagnosed with one of the following human epidermal growth factor receptor 2 (HER2)-expressing gastrointestinal cancers • Gastroesophageal adenocarcinoma • Biliary tract cancer • Colorectal cancer

Eligibility

Patients with unresectable, locally advanced, recurrent or metastatic HER2-expressing GEA, BTC, or CRC

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

First-line, study to investigate the safety, tolerability, and antitumor activity of ZW25 plus standard 1st line combination chemotherapy regimens of physician choice

For more information, visit Clinicaltrials.gov

Key Participation Requirements
Trial Location(s)
Methodist Jennie Edmundson Hospital Methodist Estabrook Cancer Center
Gender
Male or Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase II
Methodist Health System Trial Code
ZWI-ZW25-201